Financial Contrast LENZ Therapeutics (NASDAQ:LENZ) vs SOPHiA GENETICS (NASDAQ:SOPH)

LENZ Therapeutics ( NASDAQ:LENZ – Get Your Free Report ) and SOPHiA GENETICS ( NASDAQ:SOPH – Get Your Free Report ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

return

This table compares LENZ Therapeutics and SOPHiA GENETICS’ net margins, return on equity and return on assets.

Analyst recommendations

This is a summary of recent ratings and recommendations for LENZ Therapeutics and SOPHiA GENETICS as reported by MarketBeat.com.

LENZ Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 46.20%. SOPHiA GENETICS has a consensus target price of $6.50, suggesting a potential upside of 76.63%. Given SOPHiA GENETICS’ higher possible upside, analysts plainly believe SOPHiA GENETIC is more favorable than LENZ Therapeutics.

Risk and volatility

LENZ Therapeutics has a beta of 0.39, meaning its share price is 61% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.04, meaning its share price is 4% more volatile than the S&P 500.

Institutional and privileged ownership

54.3% of LENZ Therapeutics shares are owned by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 38.4% of LENZ Therapeutics shares are owned by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, big money managers and hedge funds believe a company will outperform the market over the long term.

Rating and Earnings

This table compares the gross revenue, earnings per share (EPS) and valuation of LENZ Therapeutics and SOPHiA GENETICS.

SOPHiA GENETICS has higher revenue and earnings than LENZ Therapeutics.

About LENZ Therapeutics

(Get a free report)

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of vision improvement therapies in the United States. Its product candidates include LNZ100 and LNZ101, which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

About GENETIC SOPHIA

(Get a free report)

SOPHiA GENETICS SA operates as a cloud-native healthcare software technology company. The company offers the SOPHiA DDM platform, a cloud-native software platform for data analysis and generating insights from multimodal datasets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products and services are used by hospitals, laboratories and biopharmaceutical companies through their own sales force, as well as distributors and industry collaborators in Switzerland, France, Italy, Rest of Europe, North America, United States, Latin America and Asia-Pacific. SOPHiA GENETICS SA was founded in 2011 and is based in Rolle, Switzerland.

Get news and reviews for LENZ Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for LENZ Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.